Drug Trial Radar · NCT02453282
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,118
Actual
Start
Jul 21, 2015
Primary completion
Oct 4, 2018
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- May 25, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC
Conditions
- Non-Small-Cell Lung Carcinoma NSCLC
Interventions
MEDI4736 (Durvalumab)Biological
MEDI4736 (Durvalumab)+TremelimumabBiological
Paclitaxel + CarboplatinDrug
Chemotherapy Agents
Gemcitabine + CisplatinDrug
Chemotherapy Agents
Gemcitabine + CarboplatinDrug
Chemotherapy Agents
Pemetrexed + CisplatinDrug
Chemotherapy Agents
Pemetrexed + CarboplatinDrug
Chemotherapy Agents
TremelimumabBiological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC ChemotherapyTime frame: From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).
- Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC ChemotherapyTime frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
Locations
196 sites in 17 countries. Site status is shown where the registry gives one.
Research Site
Scottsdale, Arizona
Research Site
Tucson, Arizona
Research Site
Yuma, Arizona
Research Site
Bakersfield, California
Research Site
Fullerton, California
Research Site
La Jolla, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Redondo Beach, California
Research Site
Sacramento, California
Research Site
San Luis Obispo, California
Research Site
Santa Maria, California
Research Site
West Hollywood, California
Research Site
New Haven, Connecticut
Research Site
Jacksonville, Florida
Research Site
Pembroke Pines, Florida
Research Site
Tampa, Florida
Research Site
Athens, Georgia
Research Site
Honolulu, Hawaii
Research Site
Baltimore, Maryland
Research Site
Minneapolis, Minnesota
Research Site
St Louis, Missouri
Research Site
Omaha, Nebraska
Research Site
Summit, New Jersey
Research Site
Mineola, New York
Research Site
New York, New York
Research Site
New York, New York
Research Site
New York, New York
Research Site
Charlotte, North Carolina
Research Site
Cleveland, Ohio
Research Site
North Charleston, South Carolina
Research Site
Nashville, Tennessee
Research Site
Nashville, Tennessee
Research Site
Richmond, Virginia
Research Site
Madison, Wisconsin
Research Site
Box Hill, Australia
Research Site
Gosford, Australia
Research Site
Kogarah, Australia
Research Site
Melbourne, Australia
Research Site
Port Macquarie, Australia
Showing 40 of 196 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.